Cohort of High-Grade AIN3 Anal Dysplasia FRESH-PEF8099-en Nathalie GAULT Cohort of High-Grade AIN3 Anal Dysplasia FRESH-PEF8099-en 8099 FRESH-PEF8099 Nathalie GAULT ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (AP-HP) Epidemiology France Portal (PEF) LIGUE NATIONALE CONTRE LE CANCER (LNCC) MSD FRANCE SANOFI (FRANCE) SIDACTION (ECS) SOCIETE NATIONALE FRANÇAISE DE GASTRO-ENTEROLOGIE null Laurent;ABRAMOWITZ Nathalie;GAULT High-grade anal dysplasia (AIN3) epidermoid carcinoma of the anus risk factors Oncology Infectious disease medicine Gastroenterology Carcinoma in situ of other or unspecified digestive organs Behavioral determinants The main objective of the study is the evaluation of 3-year anal carcinoma incidence in patients with anal AIN3 lesions. Secondary objectives are: - To identify patients with an anal AIN3 lesion, risk factors (demographical data, HIV status...), treatment factors (type of therapeutic treatment), virological and immunological factors (HPV genotype, presence or non-presence of P16 and Ki67 proteins) associated with the onset of epidermoid carcinoma of the anus.- To identify if the presence of P16/Ki67 factors and high risk HPV virus is associated with an increased risk of recurrent AIN3 lesions and if this is the case for high-grade dysplasia of the cervix. - To estimate the proportion of adherent patients, and to identify factors associated with compliance monitoring (demographics, HIV status, type of treatment undertaken ...) - to assess the overall feeling of patients towards anal AIN3 lesion therapeutic care. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Anal AIN3 lesion diagnosed by histology: - aposteriori for patients with a history of anal AIN3 complicated or not complicated by anal cancer. These cases will be identified from data bases of anatomopathology laboratories in hospitals since 1st January 2000. - patients consulting a proctologist at time of diagnosis for first displasic anal AIN3 lesion. Clinical data Biological data Paraclinical data (non-biological) : Imaging monthly data management queries on missing data or inconsistencies median follow-up Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception Other Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Physical/biological measurements (blood pressure, weight, biochemistry, imaging, etc.) Observational Study Observational Study Cohort study 865 Unknown Restricted access Contact the principal investigator Access on specific project only